Dangerous disease endometriosis. Why is it important to treat?
Endometriosis is a common female disease that causes significant intimate discomfort, often unbearable pain, and most importantly, it is a factor in the development of infertility and even cancer. In the structure of gynecological cases of morbidity, endometriosis firmly holds the third place after inflammatory diseases and uterine fibroids, leading to significant violations of reproductive function, persistent pain syndrome, infertility, impaired function of adjacent organs, and disability in severe cases. Endometriosis is a chronic, inflammatory gynecological condition, remains a widespread disease and it is more common among the fertile women and in 25-40% of women suffering from infertility [1,2]. It is also extremely important that modern studies indicate an increased risk of cancer among patients with endometriosis. Such women have a significantly higher risk of an ovarian cancer, cervical cancer, breast cancer, and thyroid cancer [1-3].
Nature is the wisdom of evolution. And therefore, if the women are healthy, endometrial cells should not survive in case of going beyond their normal location. Firstly, it happens because they are programmed to die (apoptosis), secondly, due to the influence of the peritoneum microenvironment, the components located in the peritoneal fluid. However, a violation of these mechanisms is noted if the patients have endometriosis. Endometrial cells successfully protect themselves from the woman's immunity, survive successfully, locate on various organs and, most importantly, acquire the properties of atypical cells: they are able to constantly multiply and migrate using vessels [2,4].
Using immune peptides, immuno-correction helps to restore a woman's immunity and destroy dangerous foci. Thanks to the effect of tissue accumulation, the immune peptides in the composition of the Arecur® drug attach to cell membranes and thus provoke T-lymphocytes to active actions. The clinical experience confirms that achieving a significant effect in fighting with endometriosis requires the use of Arecur® suppositories 2 times a day for 20 days, the course can be repeated up to 4 times a year. Arecur® does not deplete the immune system, is compatible with antibiotics, hormone therapy and chemotherapy drugs. Unlike immuno-stimulators, the immune proteins in Arecur® immuno-corrector do not deplete the immune system and do not cause immune failure, but harmoniously adjust immune cells for maximum productive work against obvious and hidden threats. Timely and complete treatment of endometriosis is the prevention of women cancer .
1.Kvaskoff M, Mahamat-Saleh Y, Farland LV, Shigesi N, Terry KL, Harris HR, Roman H, Becker CM, As-Sanie S, Zondervan KT, Horne AW, Missmer SA. Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update. 2021 Feb 19;27(2):393-420.
2.Gaia-Oltean AI, Braicu C, Gulei D, Ciortea R, Mihu D, Roman H, Irimie A, Berindan-Neagoe I. Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review). Exp Ther Med. 2021 Mar;21(3):243.
3.Eoh KJ, Han M, Kim EH, Jung I, Kim YT. Markedly increased risk of malignancies in women with endometriosis. Gynecol Oncol. 2021 Jan 26:S0090-8258(21)00079-2.
4.Murakami K, Kotani Y, Nakai H, Matsumura N. Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. Cancers (Basel). 2020;12(6):1676.
5.Zakharenko N et al. Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells. Journal of Gynecology and Obstetrics. Vol. 8, No. 5, 2020,148-153.